Mucosal healing assessment in Crohn’s disease with normalized iodine concentration from dual-energy CT enterography: comparison with endoscopy

[1] Turner D(2021)STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD Gastroenterology 160 1570-1583

[2] Ricciuto A(2019)Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn’s disease flare: a prospective cohort study Lancet Gastroenterol Hepatol 4 519-528

[3] Lewis A(2020)Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab Aliment Pharmacol Ther 52 284-291

[4] Ben-Horin S(2021)Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review Lancet Gastroenterol Hepatol 6 659-667

[5] Lahat A(2020)Deep remission at 1 year prevents progression of early Crohn’s disease Gastroenterology 159 139-147

[6] Amitai MM(2022)Toward transmural healing: sonographic healing is associated with improved long-term outcomes in patients with Crohn’s disease Aliment Pharmacol Ther 56 84-94

[7] Bertani L(2021)Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease Aliment Pharmacol Ther 53 577-586

[8] Fornai M(2022)A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab Eur Radiol 32 6628-6636

[9] Fornili M(2012)Endoscopic skipping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy Clin Gastroenterol Hepatol 10 1253-1259

[10] Geyl S(2020)Normalization of C-reactive protein predicts better outcome in patients With Crohn’s disease with mucosal healing and deep remission Clin Transl Gastroenterol 11 e00135-799

[1] Turner D(2021)STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD Gastroenterology 160 1570-1583

[2] Ricciuto A(2019)Assessment of small bowel mucosal healing by video capsule endoscopy for the prediction of short-term and long-term risk of Crohn’s disease flare: a prospective cohort study Lancet Gastroenterol Hepatol 4 519-528

[3] Lewis A(2020)Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab Aliment Pharmacol Ther 52 284-291

[4] Ben-Horin S(2021)Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review Lancet Gastroenterol Hepatol 6 659-667

[5] Lahat A(2020)Deep remission at 1 year prevents progression of early Crohn’s disease Gastroenterology 159 139-147

[6] Amitai MM(2022)Toward transmural healing: sonographic healing is associated with improved long-term outcomes in patients with Crohn’s disease Aliment Pharmacol Ther 56 84-94

[7] Bertani L(2021)Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn’s disease Aliment Pharmacol Ther 53 577-586

[8] Fornai M(2022)A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab Eur Radiol 32 6628-6636

[9] Fornili M(2012)Endoscopic skipping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy Clin Gastroenterol Hepatol 10 1253-1259

[10] Geyl S(2020)Normalization of C-reactive protein predicts better outcome in patients With Crohn’s disease with mucosal healing and deep remission Clin Transl Gastroenterol 11 e00135-799